Results 1 to 10 of about 1,337 (103)

Vericiguat reduces electrical and structural remodeling in a rabbit model of atrial fibrillation

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Purpose: The molecular etiology of atrial fibrillation (AF) and its treatment are poorly understood. AF involves both electrical and structural features. Vericiguat can ameliorate cardiac remodeling in heart failure.
Weimin Li, Guangzhong Liu, Qi Lou
exaly   +2 more sources

Vericiguat Attenuates Vascular Calcification by Cyclic Guanosine Monophosphate‐Protein Kinase G Pathway Mediated Suppression of Matrix Metalloproteinase 10 [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Vascular calcification (VC), a pathological process driven by the osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs), markedly increases cardiovascular mortality.
Qing‐Yun Hao, Yu‐Hong Zeng, Zi‐Bin Zhan, Xue‐Wen Liu, Jing‐Bin Guo, Kun‐Hao Bai, Jun Weng, Jing‐Wei Gao, Ze‐Hua Li   +8 more
doaj   +2 more sources

Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction and asymptomatic hypotension: insights from a multicenter observational cohort study [PDF]

BMC Cardiovascular Disorders
Background Recent VICTOR study and the VICTORY pooled analysis demonstrate that vericiguat shows significant therapeutic value in a broader population of relatively stable heart failure with reduced ejection fraction (HFrEF) patients.
Jiangyue Tian, Shufang Chen, Guihua Zhang, Xiaoning Jia, Luyao An, Xuyang Duan, Yarui Zhao, Changjiang Wei, Huafang Zhang, Xiaowei Li, Kecai Lu, Guihua Yao, Qing Ye, Huixia Lu   +13 more
doaj   +2 more sources

Efficacy of Vericiguat in Acute Heart Failure: A Target Trial Emulation Study [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In recent trials, vericiguat reduced adverse cardiovascular outcomes in stable or recently worsening chronic heart failure (HF), although data concerning vericiguat use in the population with acute HF remain limited.
Junlong Chen, Jian Liu, Ruo’nan Xiao, Yichen Wang, Lei Gao, Wenhang Zhao, Ziyang Li, Siyi He, Yihang Zhang, Xuesong Wen, Dongying Zhang   +10 more
doaj   +2 more sources

Vericiguat: A New Horizon for Heart Failure Treatment [PDF]

Reviews in Cardiovascular Medicine
Despite advances in guideline-directed medical therapy (GDMT), heart failure with reduced ejection fraction (HFrEF) remains a progressive condition with high morbidity and mortality.
Carla Carbonaro, Pier Paolo Bocchino, Eleonora Bertello, Carola Griffith Brookles, Filippo Angelini, Guglielmo Gallone, Stefano Pidello, Amedeo Feneziani, Claudia Raineri, Gaetano Maria De Ferrari   +9 more
doaj   +2 more sources

Vericiguat for endothelial dysfunction and CRT response in non-responders: the VERCET prospective observational study [PDF]

BMC Medicine
Background Endothelial dysfunction (ED) is a negative prognostic factor for patients with heart failure (HF) who are treated with cardiac resynchronization therapy (CRT).
Celestino Sardu, Ludovica Vittoria Marfella, Luca Rinaldi, Ferdinando Carlo Sasso, Domenico Cozzolino, Francesco Nappo, Ausilia Sellitto, Ciro Romano, Caterina Carusone, Nunzia D’Onofrio, Maria Consiglia Trotta, Joshua Riccio, Domenico Cioffi, Mario Volpicelli, Carmine La Marca, Natale Marrazzo, Valerio Giordano, Carlo Fumagalli, Alessandro Landolfi, Marianna Abitabile, Lorenza Marfella, Maria Luisa Balestrieri, Raffaele Marfella   +22 more
doaj   +2 more sources

Vericiguat attenuates cyclosporine A-induced nephropathy by targeting the NF-κB/TGF-β1 axis: an integrated network pharmacology, Mendelian randomization, and experimental study [PDF]

Frontiers in Immunology
BackgroundCyclosporine A (CsA)-induced nephrotoxicity is a significant cause of chronic kidney disease (CKD), primarily driven by aberrant activation of the NF-κB and TGF-β1 signaling axes.
XuanKe Liu, XuanKe Liu, MengJie Tang, MengJie Tang, JiaYing Lu, JiaYing Lu, YiJing Kong, YiJing Kong, WenXuan Shen, WenXuan Shen, ChunJiang Zhang, ChunJiang Zhang, XiaoPing Yang, XiaoPing Yang   +13 more
doaj   +2 more sources

Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial

Journal of the American Heart Association, 2021
Background Although safety and tolerability of vericiguat were established in the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial in patients with heart failure with reduced ejection fraction, some ...
Yuri Lopatin, Paul W Armstrong, Justin Ezekowitz   +2 more
exaly   +3 more sources

One-year real-world outcomes after vericiguat initiation in heart failure: The ROVER-Japan cohort study [PDF]

International Journal of Cardiology: Heart & Vasculature
Background: Vericiguat, a soluble guanylate cyclase stimulator, is recommended for patients with chronic heart failure (HF) who recently worsened despite guideline-directed medical therapy. However, there is limited data on its real-world utilization and
Makiko Takeichi, Shun Kohsaka, Kotaro Nochioka, Christoph Ohlmeier, Alexander Michel, Katsiaryna Holl, Hiroki Yamamoto, Yoshifumi Arita, Seok-Won Kim, Suguru Okami   +9 more
doaj   +2 more sources

Efficacy and safety of vericiguat in heart failure: a meta-analysis

Journal of International Medical Research, 2023
Objective This study aimed to investigate the safety and efficacy of vericiguat in patients with heart failure (HF). Methods We conducted a comprehensive literature review of the PubMed, Embase, and Cochrane Library databases up to 14 December 2022 for ...

exaly   +2 more sources